Biomedix Signs Strategic Distribution Agreement With BeamMed Ltd
Expands Biomedix Xchange Population Health Management Solution
Today at the RISE National 2020 Conference, BeamMed Ltd and Biomedix, LLC announce the signing of a strategic distribution agreement that expands the Biomedix Xchange Population Health Management Solution to include BeamMed’s MiniOmni bone density diagnostic technology.
“The MiniOmni is an exceptionally affordable professional solution for the early assessment of osteoporosis. It enables reliable, accurate, non-invasive monitoring of bone density in an ultra-portable form factor. With an intuitive interface, and convenient USB-port connectivity to Windows™ devices, it is ideal for integration into the Biomedix population health management solution,” said Gilad Zamir, VP Sales & Marketing at BeamMed Ltd.
“Given the MiniOmni is the preferred bone density HEDIS solution for many of the leading Medicare Advantage Plans and HRA Service Providers, and our PADnet technology has been a market leader in peripheral artery disease (PAD) detection with over 1 million PAD tests performed, a strategic partnership was a natural fit,” stated Rich Delperdang, Chief Growth Officer at Biomedix. “Integrating these diagnostic capabilities that support Quality and Risk measures into our HITRUST- certified population health management solution offers unparalleled access to patient data in a way that cost-effectively enables providers and plans to collaborate in a manner that is safe, reliable, and fast.”
Biomedix is a provider of front-line diagnostic solutions for delivering value-based care. Biomedix Xchange is a population health solution that centralizes data for analyzing population health across multiple chronic conditions. For more information, visit Biomedix.com.
About PADnet & PADnet Xpress
Biomedix is the maker of PADnet, the market leader in front-line diagnostics for peripheral vascular disease. PADnet is the only diagnostic device that can support the identification of PAD and chronic venous insufficiency (CVI) through a unique collaborative care model. PADnet Xpress represents the latest technology for quick and accurate PAD detection, custom-designed for value-based care, including Medicare Advantage Organizations (MAOs).
BeamMed develops, manufactures, and markets bone density assessment solutions. In particular, BeamMed lead the market with advanced ultrasound technology and portable bone density devices that enable physicians to provide early assessment, diagnosis, and monitoring of osteoporosis and to assess bone development. BeamMed’s devices leverage the patented Omnipath™ axial transmission technology that effectively screens for osteoporosis and improves HEDIS measures, allowing reaching 5-stars rating for HEDIS OMW.